Tularik and Amgen entered into 5-year research and development agreement to discover, develop and commercialize oncology therapeutics including T67, a small molecule that binds to beta-tubulin that is in phase II clinical trials for the treatment of hepatocellular carcinoma and T607, which is in phase II clinical trials for the treatment of hepatocellular carcinoma, ovarian cancer, gastric cancer and esophageal cancer. Tularik could receive US$50 M as research funding in addition to US$21 M if specific milestones and sales targets are met.